PDCD1 and liposarcoma: To date, there are only a few available studies both exploring the antitumor efficacy of PD-1 inhibition as a monotherapy 77 and its combinatorial effect with the oncolytic vaccinia virus (GLV-1h68) 78, in a model of dedifferentiated liposarcoma and liposarcoma (of unspecified histological subtype), respectively.